Recombinant Human AHSP Protein，GST

ASXL1 (Additional Sex Combs Like 1) is a gene that plays a crucial role in epigenetic regulation and chromatin remodeling. Mutations in ASXL1 have been linked to various hematological malignancies, particularly myeloid malignancies such as Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS). These mutations often result in a loss of function, leading to abnormal gene expression and disrupted cellular differentiation processes. The ASXL1 protein is known to function as a component of the Polycomb Repressive Complex 2 (PRC2), influencing gene silencing and maintaining cell identity. Research has shown that ASXL1 mutations are associated with poor prognosis and may contribute to the pathogenesis of malignancies by promoting hematopoietic stem cell self-renewal and impairing differentiation. Recent studies have also examined the interaction of ASXL1 with other oncogenic pathways and its role in the response to therapy. Understanding the molecular mechanisms by which ASXL1 mutations drive tumorigenesis is critical for developing targeted therapies and improving patient outcomes in cancers where ASXL1 alterations are prevalent. Furthermore, the exploration of ASXL1 as a potential biomarker for diagnosis and prognostication in hematological cancers remains an area of active investigation, underscoring its significance in both clinical and research settings.